These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
212 related items for PubMed ID: 34013992
21. Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial. Ashina M, Tepper SJ, Gendolla A, Sperling B, Ettrup A, Josiassen MK, Starling AJ. J Headache Pain; 2023 Nov 20; 24(1):155. PubMed ID: 37985968 [Abstract] [Full Text] [Related]
22. Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials. Schim JD, Anderson C, Brunner E, Hirman J, Ogbru A, Cady R, McGill L. Headache; 2022 May 20; 62(5):558-565. PubMed ID: 35524405 [Abstract] [Full Text] [Related]
23. Eptinezumab for migraine prevention in patients 50 years or older. Martin V, Tassorelli C, Ettrup A, Hirman J, Cady R. Acta Neurol Scand; 2022 Jun 20; 145(6):698-705. PubMed ID: 35218203 [Abstract] [Full Text] [Related]
24. Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2. Martin V, Nagy AJ, Janelidze M, Giorgadze G, Hirman J, Cady R, Mehta L, Buse DC. Clin Ther; 2022 Mar 20; 44(3):389-402. PubMed ID: 35131090 [Abstract] [Full Text] [Related]
25. Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study. Barbanti P, Goadsby PJ, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B. J Headache Pain; 2022 Dec 02; 23(1):153. PubMed ID: 36460983 [Abstract] [Full Text] [Related]
26. Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study. Cowan RP, Marmura MJ, Diener HC, Starling AJ, Schim J, Hirman J, Brevig T, Cady R. J Headache Pain; 2022 Sep 06; 23(1):115. PubMed ID: 36068494 [Abstract] [Full Text] [Related]
27. Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine. McAllister P, Kudrow D, Cady R, Hirman J, Ettrup A. Cephalalgia; 2022 Sep 06; 42(10):1005-1012. PubMed ID: 35332807 [Abstract] [Full Text] [Related]
28. Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine. Pederson S, Biondi DM, Allan B, Cady R, Schaeffler B, Baker B, Latham J. Front Immunol; 2021 Sep 06; 12():765822. PubMed ID: 34759933 [Abstract] [Full Text] [Related]
30. Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study. Cady R, Lipton RB, Buse DC, Josiassen MK, Lindsten A, Ettrup A. J Headache Pain; 2022 Jul 28; 23(1):91. PubMed ID: 35902796 [Abstract] [Full Text] [Related]
31. Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing. Dodick DW, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S. Headache; 2020 Nov 28; 60(10):2220-2231. PubMed ID: 33165938 [Abstract] [Full Text] [Related]